RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510926-19-00

Enrollment

Registered

2025-11-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026